Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line-Reference-Cited by-同舟云学术

Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line

Published:1995-07-04 Issue:1 Volume:62 Page:97-102
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Barker Alexander B. H.,Schreurs Marco W. J.,Tafazzul Gaalda,De Boer Annemiek J.,Kawakami Yutaka,Adema Gosse J.,Figdor Carl G.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference31 articles.

1. Molecular characterization of the melanocyte lineage-specific antigen gp100.

2. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.

3. Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53

4. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The landscape of T cell antigens for cancer immunotherapy;Nature Cancer;2023-07-06

2. Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy;Nature Biotechnology;2023-01-02

3. Therapeutic Cancer Vaccines—Antigen Discovery and Adjuvant Delivery Platforms;Pharmaceutics;2022-07-11

4. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma;Cancers;2021-11-27

5. ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope;European Journal of Immunology;2019-11-27